Please use this identifier to cite or link to this item:
http://hdl.handle.net/1843/60917| Type: | Artigo de Periódico |
| Title: | Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression |
| Authors: | Luciana Mendes Araújo Borém Sergio Henrique Sousa Santos Daniela Fernanda de Freitas Amanda Souto Machado Alanna Fernandes Paraiso Bruna Viana Caldas João Felício Rodrigues Neto Juliana Pinto Lima André Luiz Senna Guimarães Alfredo Mauricio Batista de Paula |
| Abstract: | Background Telmisartan is a non-peptide angiotensin II receptor antagonist which acts by ACE/AngII/AT1 axis blockade (ARB). In the last years increasing evidence of its metabolic benefits pointed out this drug as the most promising ARB for nonalcoholic fatty liver disease (NAFLD) treatment. The aim of the present study was to investigate the Telmisartan effect on treating NAFLD in mice fed with a high-fat diet evaluating liver gene modulation. Twenty-four male mice were divided into four groups and fed for 60 days with a standard diet (ST), standard diet plus TEL (ST+TEL 5 mg/kg/day by gavage for 4 weeks), high-fat diet (HFD), or high-fat diet plus TEL (HFD+TEL 5 mg/kg/day by gavage for 4 weeks). Body weight, lipid profile, insulin, alanine transaminase, and aspartate aminotransferase were evaluated. Liver histology was analyzed. US imaging was performed to access liver dimension and echogenicity and also epididymal fat pad thickness. The expression of proinflammatory resistin/TRL4/MYD88 pathway was analyzed. Results The main findings showed that TEL reduced the resistin, TRL4, and Myd88 liver expression in the HFD + TEL group when compared to the obese control group (HFD). Decreased hepatic steatosis in the HFD + TEL group demonstrated by US measurements of the liver longitudinal axis and echogenicity were observed. In addition, TEL reduced epididymal adipose pad thickness, body weight, transaminases, and improved glucose tolerance test and HDL cholesterol. Conclusions We observed that Telmisartan treatment improved metabolism, decreasing NAFLD. |
| Subject: | Obesidade Fígado |
| language: | eng |
| metadata.dc.publisher.country: | Brasil |
| Publisher: | Universidade Federal de Minas Gerais |
| Publisher Initials: | UFMG |
| metadata.dc.publisher.department: | ICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS |
| Rights: | Acesso Aberto |
| metadata.dc.identifier.doi: | https://doi.org/10.1186/s43066-022-00216-w |
| URI: | http://hdl.handle.net/1843/60917 |
| Issue Date: | 14-Sep-2022 |
| metadata.dc.url.externa: | https://eglj.springeropen.com/articles/10.1186/s43066-022-00216-w#rightslink |
| metadata.dc.relation.ispartof: | Egyptian Liver Journal |
| Appears in Collections: | Artigo de Periódico |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression.pdf | 1.32 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.